Literature DB >> 24856951

Distinguishing nontuberculous mycobacteria from multidrug-resistant Mycobacterium tuberculosis, China.

Kaijin Xu, Sheng Bi, Zhongkang Ji, Haiyang Hu, Feisu Hu, Beiwen Zheng, Bing Wang, Jingjing Ren, Shigui Yang, Min Deng, Ping Chen, Bing Ruan, Jifang Sheng, Lanjuan Li.   

Abstract

Entities:  

Keywords:  China; MDR TB; Mycobacterium tuberculosis; multidrug-resistant Mycobacterium tuberculosis; nontuberculous Mycobacteria; tuberculosis; tuberculosis and other mycobacteria

Mesh:

Substances:

Year:  2014        PMID: 24856951      PMCID: PMC4036753          DOI: 10.3201/eid2006.130700

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Mycobacteria are commonly characterized by positive acid-fast staining. Most mycobacterial species belong to the nontuberculous mycobacteria (NTM), excluding species in the Mycobacterium tuberculosis complex and M. leprae. Both M. tuberculosis and NTM can induce pulmonary infection with similar symptoms and pulmonary radiographic findings (). These similarities have led to difficulty in distinguishing these infections clinically. As in many developing countries, the acid-fast stain is the only bacteriologic basis for diagnosing tuberculosis (TB) in primary health care institutions in China, where facilities are limited for M. tuberculosis culture, strain identification, and drug resistance detection. Thus, NTM is easily misdiagnosed as M. tuberculosis, and multidrug-resistant (MDR) TB is unable to be accurately identified. Patients with misdiagnosed TB usually are treated with the standard anti-TB regimens recommended by the Chinese government (i.e., 2HRZE/4HR [2 months of isoniazid (INH), rifampin (RIF), pyrazinmid, and ethambutol, followed by 4 months of INH and RIF 1 time daily] and 2H3R3Z3E3/4H3R3 [2 months of INH, RIF, pyrazinamide, and ethambutol followed by 4 months of INH and RIF 3 times weekly]) (), which often results in treatment failures. Misdiagnosis is a key hurdle for effective prevention and treatment of TB (–). To evaluate the effect of misdiagnosis on TB prevention, we determined the proportion of patients with MDR TB and NTM infection in primary health care institutions in Zhejiang Province, China. Our findings would be useful for improving TB prevention and treatment. During 2011–2012, sputum samples from 13,882 patients suspected of having TB in 8 counties in Zhejiang Province were used to culture mycobacteria. Each sample was seeded onto 2 pieces of Löwenstein-Jensen medium. A total of 1,410 samples grew mycobacteria confirmed as acid-fast bacilli by using Ziehl-Neelsen staining. The 1,410 samples were further identified by using the Mycobacteria Identification Array Kit (CapitalBio, Beijing, China). The kit contains 17 types of bacilli-specific 16S rRNA probes (i.e., M. tuberculosis complex, M. avium, M. intracellulare, M. gilvum, M. xenopi, M. smegmatis, M. aurum, M. terrae, M. gordonae, M. chelonae/abscessus, M. phlei, M. scrofulaceum, M. fortuitum, M. szulgai, M. ulcerans, M. marinum, and M. kansasii). With this method, M. tuberculosis and NTM can be distinguished, and the species of NTM can be identified (–). Of 1,410 positive strains, we identified 1,332 (94.5%) as M. tuberculosis and 78 (5.5%) as NTM. NTM strains were further identified as follows: M. intracellulare, 39 isolates; M. chelonae/abscessus, 12 isolates, M. kansasii, 13 isolates; M. avium, 3 isolates; M. fortuitum, 4 isolates; and M. scrofulaceum and M. szulgai, 1 isolate each. For 5 isolates, strain could not be classified. We detected drug resistance of 1,332 M. tuberculosis strains using a Tuberculosis Drug Resistance Detection Array Kit (CapitalBio) (). The mutant points for RIF resistance were identified as follows: rpoB/C531G, C531T, CG531AC, A526C, A526G, A526T, C526A, C526G, C526T, T533C, A516G, A516T, G516T, T511C, T511G, C513A, A513T, and C522T (Table). Moreover, the kit contained 5 mutant points for INH resistance, including katG (G315A, G315C, G315T, and C315) and inhA (C-15T) (Table). Of 1,332 M. tuberculosis strains, we identified 1,115 (83.7%) RIF/INH-sensitive strains, 88 (6.6%) MDR TB strains, 83 (6.2%) INH-resistant strains, and 47 (3.5%) RIF-resistant strains. Of the 1,410 positive strains, 88 (6.2%) were MDR M. tuberculosis strains.
Table

Gene mutations of 214 drug-resistant tubercle bacilli, Zhejiang Province, China, 2011–2012

Drug
Mutant points
Mutant times
Mutant times for single site, no. (%)*
Total no. mutant times of sites related to drug resistance
IsoniazidinhA-15 (C→T)32 (18.6)172†

katG315 (G→C), (G→A)
140 (81.4)

RifampinrpoB511 (T→C)10 (7.1)140‡
rpoB513 (A→C)2 (1.4)
rpoB516 (A→T), (A→G), (G→T)19 (13.6)
rpoB526 (A→G), (A→T), (C→G), (C→T)21 (15)
rpoB531 (C→G), (C→T)84 (60.0)
rpoB533 (T→C)4 (2.9)

*No. mutant times for single site/total no. mutant times of sites related to drug resistance.
†A strain simultaneously had katG315 (G→C) and inhA-15 (C→T).
‡Five strains had the double mutation of rpoB.

*No. mutant times for single site/total no. mutant times of sites related to drug resistance.
†A strain simultaneously had katG315 (G→C) and inhA-15 (C→T).
‡Five strains had the double mutation of rpoB. The epidemiology of TB in Zhejiang Province reflects the situation in China and some developing countries (). The clinical diagnosis and treatment of >80% TB cases in China is performed mainly by primary health care institutions. However, almost 80% of these medical institutions do not have the capability to culture M. tuberculosis, detect drug resistance, and identify strains (). Of 1,410 strains obtained from the patients in 8 counties of Zhejiang Province, 218 (15.5%) were MDR TB, INH resistant, and RIF resistant. These affected patients could not be effectively treated with the national standard regimens. Specifically, 88 patients with MDR TB would be at risk for extensively drug-resistant TB, and 83 patients with INH-resistant TB and 47 with RIF-resistant TB would be at risk for MDR TB. In addition, we identified 78 (5.5%) NTM strains. With the acid-fast stain, these illnesses would be misidentified as TB and, in most instances, also would be reported as treatment failures. Clearly, accurate diagnosis provided by the technologies used in this study for distinguishing NTM and M. tuberculosis, Mycobacterium strain identification, and drug-resistance detection would increase the cure rate and effectively prevent TB epidemics. For INH resistance, katG315 was a main mutant point of the M. tuberculosis strain; 140 (81.4%) of the 172 INH-resistant mutations were related to katG315. For RIF resistance, rpoB531 was a main mutant point; 84 (60.0%) of 140 RIF-resistant mutations were associated with rpoB531. Therefore, in future studies, more attention should be paid to the molecular epidemiology of katG315 and rpoB531. In conclusion, using the techniques for M. tuberculosis culture, Mycobacterium strain identification, and drug-resistance detection is necessary. It should be urgently pursued for accurate TB diagnosis in primary health care institutions in China to improve the prevention, treatment, and control of TB.
  8 in total

1.  Rapid molecular identification of mycobacterial species in positive culture isolates using the biochip test.

Authors:  Y Pang; Y Zhou; S Wang; Y Tan; J Yue; B Zhao; L Wang; Y Zhao; K M Kam
Journal:  Int J Tuberc Lung Dis       Date:  2011-12       Impact factor: 2.373

2.  Guidelines on the diagnosis and treatment of pulmonary non-tuberculous mycobacteria infection.

Authors:  E E McGrath; J McCabe; P B Anderson
Journal:  Int J Clin Pract       Date:  2008-12       Impact factor: 2.503

3.  Biochip system for rapid and accurate identification of mycobacterial species from isolates and sputum.

Authors:  Lingxiang Zhu; Guanglu Jiang; Shengfen Wang; Can Wang; Qiang Li; Hao Yu; Yang Zhou; Bing Zhao; Hairong Huang; Wanli Xing; Keith Mitchelson; Jing Cheng; Yanlin Zhao; Yong Guo
Journal:  J Clin Microbiol       Date:  2010-08-04       Impact factor: 5.948

4.  Multi-centre evaluation of the speed-oligo Mycobacteria assay for differentiation of Mycobacterium spp. in clinical isolates.

Authors:  Sabine Hofmann-Thiel; Laziz Turaev; Tarig Alnour; Lore Drath; Maria Müllerova; Harald Hoffmann
Journal:  BMC Infect Dis       Date:  2011-12-19       Impact factor: 3.090

5.  Performance assessment of the CapitalBio mycobacterium identification array system for identification of mycobacteria.

Authors:  Jingbo Liu; Jun Yue; Zihe Yan; Min Han; Zhijun Han; Lingjie Jin; Yanlin Zhao
Journal:  J Clin Microbiol       Date:  2011-11-16       Impact factor: 5.948

6.  National survey of drug-resistant tuberculosis in China.

Authors:  Yanlin Zhao; Shaofa Xu; Lixia Wang; Daniel P Chin; Shengfen Wang; Guanglu Jiang; Hui Xia; Yang Zhou; Qiang Li; Xichao Ou; Yu Pang; Yuanyuan Song; Bing Zhao; Hongtao Zhang; Guangxue He; Jing Guo; Yu Wang
Journal:  N Engl J Med       Date:  2012-06-07       Impact factor: 91.245

7.  Rapid, accurate determination of multidrug resistance in M. tuberculosis isolates and sputum using a biochip system.

Authors:  Y Guo; Y Zhou; C Wang; L Zhu; S Wang; Q Li; G Jiang; B Zhao; H Huang; H Yu; W Xing; K Mitchelson; Jing Cheng; Yanlin Zhao
Journal:  Int J Tuberc Lung Dis       Date:  2009-07       Impact factor: 2.373

8.  Failure to recognize nontuberculous mycobacteria leads to misdiagnosis of chronic pulmonary tuberculosis.

Authors:  Mamoudou Maiga; Sophia Siddiqui; Souleymane Diallo; Bassirou Diarra; Brehima Traoré; Yvonne R Shea; Adrian M Zelazny; Bindongo P P Dembele; Drissa Goita; Hamadoun Kassambara; Abdulrahman S Hammond; Michael A Polis; Anatole Tounkara
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

  8 in total
  7 in total

1.  "Multidrug-resistant tuberculosis" may be nontuberculous mycobacteria.

Authors:  Abdolrazagh Hashemi Shahraki; Parvin Heidarieh; Saeed Zaker Bostanabad; Azar Dokht Khosravi; Mohammad Hashemzadeh; Solmaz Khandan; Maryam Biranvand; Dean E Schraufnagel; Mehdi Mirsaeidi
Journal:  Eur J Intern Med       Date:  2015-03-14       Impact factor: 4.487

2.  Evaluation of the inflammatory response in macrophages stimulated with exosomes secreted by Mycobacterium avium-infected macrophages.

Authors:  Jianjun Wang; Yongliang Yao; Jing Xiong; Jianhong Wu; Xin Tang; Guangxin Li
Journal:  Biomed Res Int       Date:  2015-03-16       Impact factor: 3.411

3.  Clinical significance of smear positivity for acid-fast bacilli after ≥5 months of treatment in patients with drug-susceptible pulmonary tuberculosis.

Authors:  Hyung Koo Kang; Byeong-Ho Jeong; Hyun Lee; Hye Yun Park; Kyeongman Jeon; Hee Jae Huh; Chang-Seok Ki; Nam Yong Lee; Won-Jung Koh
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

4.  Surveillance of Tuberculosis in Taipei: The Influence of Nontuberculous Mycobacteria.

Authors:  Chen-Yuan Chiang; Ming-Chih Yu; Shiang-Lin Yang; Muh-Yong Yen; Kuan-Jen Bai
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

5.  A pilot study: VereMTB detection kit for rapid detection of multidrug-resistant mycobcterium tuberculosis in clinical sputum samples.

Authors:  Xichao Ou; Qiang Li; Dan Su; Hui Xia; Shengfen Wang; Bing Zhao; Yanlin Zhao
Journal:  PLoS One       Date:  2020-03-09       Impact factor: 3.240

6.  Comprehensive Determination of Mycobacterium tuberculosis and Nontuberculous Mycobacteria From Targeted Capture Sequencing.

Authors:  Ya He; Ziying Gong; Xiaokai Zhao; Daoyun Zhang; Zhongshun Zhang
Journal:  Front Cell Infect Microbiol       Date:  2020-09-01       Impact factor: 5.293

7.  Sentinel site surveillance of nontuberculous mycobacteria pulmonary diseases in Zhejiang, China, 2011-2013.

Authors:  Sheng Bi; Kai-Jin Xu; Zhong-Kang Ji; Bei-Wen Zheng; Ji-Fang Sheng
Journal:  Braz J Infect Dis       Date:  2015-09-09       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.